For someone who won't take an injection, 10 percent weight loss is infinitely better than zero.
Across India, a quiet revolution in how obesity is treated is taking shape — not through dramatic scientific breakthroughs, but through the humble form of a tablet. By year's end, a wave of oral GLP-1 weight-loss pills from Chinese biotech firms and Western manufacturers will reach a market long dominated by injectable therapies, offering a path to treatment that aligns with how most Indians already prefer to take medicine. The significance lies not merely in new drugs arriving, but in the possibility that millions who would never have accepted a needle may now accept help.
- A crowded pipeline of nearly a dozen oral GLP-1 molecules — from firms like Hengrui, Innovent Biologics, and Eli Lilly — is converging on the Indian market simultaneously, signaling a structural shift rather than a marginal update.
- The real disruption is economic and logistical: small-molecule compounds require no cold storage and cost less to manufacture, dismantling two of the biggest barriers to obesity treatment access in a country with uneven infrastructure.
- India's 75% oral-medicine preference and widespread needle phobia mean the patient population most likely to benefit was never going to be reached by injectables — oral formulations don't just compete with existing treatments, they open an entirely new front.
- Endocrinologists are divided — some warn of bioavailability limitations and harsher gastrointestinal side effects, while others argue that even 10–15% weight loss is transformative for patients who would otherwise refuse treatment entirely.
- Indian pharmaceutical companies are already moving to partner with Chinese biotech firms for clinical rights and local manufacturing, accelerating market entry and pushing costs lower still.
- The infrastructure is assembling, but mass adoption remains conditional — price points, tolerability profiles, and patient willingness to try something new will determine whether this moment becomes a turning point or a missed opportunity.
By year-end, India's obesity treatment landscape will look markedly different. A cascade of oral weight-loss pills — from Chinese biotech companies including Hengrui, Huadong, and Innovent Biologics, as well as Eli Lilly's non-peptide tablet orforglipron — is set to arrive, and industry executives and endocrinologists say the shift will be substantial. Novo Nordisk's oral semaglutide is already on the market for diabetes, generating 500 crore rupees in sales since 2022, offering a glimpse of what appetite exists.
What makes these pills genuinely significant is their design. Many are small-molecule or non-peptide compounds — cheaper to manufacture, free of cold-storage requirements, and delivered as tablets rather than injections. In a country where over 75 percent of patients prefer oral medication and needle phobia is widespread, this is not a minor convenience. Mumbai diabetologist Dr. Rajiv Kovil frames it plainly: these options could reach patients who were never going to accept injectable therapy in the first place. A 10 to 15 percent weight-loss efficacy, modest by clinical standards, may be more than sufficient for someone who would otherwise avoid treatment altogether.
Indian pharmaceutical companies are already positioning for this shift, with domestic firms expected to partner with Chinese biotech companies for clinical development and commercial rights — mirroring existing arrangements in the injectable space. These partnerships will accelerate market entry and localize manufacturing, pressing costs lower still.
Skepticism remains measured but real. Some endocrinologists flag concerns about bioavailability and gastrointestinal side effects more pronounced than those seen with injections, and note that a once-weekly injection may in practice be simpler than daily tablet adherence. Non-peptide compounds could prove transformative, but that potential remains conditional on resolving tolerability and efficacy challenges. What is certain is that the market is moving — and the question now is whether patients will meet it.
By year-end, India's obesity treatment landscape will look markedly different. A cascade of oral weight-loss pills—some from Chinese biotech firms, others from established Western manufacturers—is about to arrive in the Indian market, and industry executives and leading endocrinologists say the shift will be substantial. These tablets represent a fundamental departure from the injectable GLP-1 drugs that have dominated obesity treatment until now, offering something simpler, cheaper, and far more aligned with how Indians actually take medicine.
The pipeline is crowded. Nearly a dozen oral GLP-1 molecules are in development at Chinese biotech companies including Hengrui, Huadong, Innovent Biologics, and Ascletis. Eli Lilly is expected to launch its non-peptide tablet orforglipron by year-end. Novo Nordisk already has oral semaglutide, marketed as Rybelsus, on the market for diabetes treatment since 2022, where it has generated 500 crore rupees in sales. Structure Therapeutics, a US firm, is working on aleniglipron in Phase 2 trials. The sheer number of candidates suggests that what was once a niche category is becoming crowded.
What makes these pills genuinely transformative is not just their existence but their design. Many of the Chinese options—including Huadong's conveglipron and Hengrui's HRS 7535—are non-peptide or small-molecule compounds. This matters economically. Small molecules are cheaper to manufacture than peptide-based drugs, which means they can be produced at scale and priced lower. They don't require cold storage, a critical advantage in a country where reliable refrigeration cannot be assumed everywhere. They are tablets, not needles. For a healthcare system where over 75 percent of patients prefer oral medication, this alignment is not incidental—it is the entire point.
Dr. Rajiv Kovil, a diabetologist in Mumbai, frames the opportunity plainly: pills like Lilly's orforglipron and the incoming Chinese options could make treatment cheaper and easier. The weight-loss efficacy of these oral formulations ranges from 10 to 16 percent, which is meaningful but not dramatic. Yet for patients who fear needles, who worry about lifelong injections, who feel that injectable therapy is overkill for borderline obesity, or who simply prefer the routine of swallowing a tablet, this efficacy gap may be irrelevant. Kovil notes that 10 to 15 percent weight loss could be sufficient for needle-phobic patients who would otherwise avoid treatment altogether. The market expansion, in other words, may come not from converting existing patients but from reaching people who were never going to take an injection in the first place.
Indian pharmaceutical companies are already positioning themselves. Industry observers expect domestic firms to partner with Chinese biotech companies for clinical development and commercial rights, mirroring existing arrangements in the injectable space—Lupin, for instance, partners with Gan & Lee Pharmaceuticals for the twice-monthly injectable GLP-1 drug bofanglutide. These partnerships will accelerate Indian market entry and localize manufacturing, further reducing costs.
But skepticism exists. Some endocrinologists worry about bioavailability—the amount of drug that actually reaches the bloodstream when taken orally—and patient tolerability. Neeraj Tulara, a leading diabetologist, points out that oral GLP-1 therapies may cause more severe gastrointestinal side effects, including nausea and vomiting, than injections. He also notes that for many patients, a once-weekly injection may be simpler than daily tablet adherence. Venkatesh Shivane, a senior endocrinologist at Jaslok Hospital in Mumbai, suggests that non-peptide compounds could be genuine game-changers if they overcome efficacy and tolerability hurdles, but that remains conditional.
What is certain is that the market is moving. By the time this year ends, Indians seeking obesity treatment will have choices their counterparts did not have six months ago. Whether those choices translate into mass adoption depends on price, tolerability, and the willingness of patients to try something new. The infrastructure is being built. The question now is whether patients will use it.
Citações Notáveis
With pills like oral Wegovy and Foundayo and newer options from China, treatment could become cheaper and easier. Unlike injections, these tablets don't need cold storage and are more convenient which matters a lot in India.— Dr. Rajiv Kovil, diabetologist, Mumbai
If oral GLP-1 comes in non-peptide compound, it will be the game changer in the long term—both in terms of efficacy and ease of usage.— Dr. Venkatesh Shivane, senior endocrinologist, Jaslok Hospital, Mumbai
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that these pills are coming from China specifically?
Cost. Chinese biotech firms have developed small-molecule compounds that are far cheaper to manufacture than the peptide-based injectables that dominate now. That manufacturing advantage translates directly to price, which matters enormously in a price-sensitive market like India.
But aren't there already oral weight-loss drugs available?
Novo has oral semaglutide for diabetes since 2022, but that's a different indication and a different market. What's new is the volume of candidates specifically for obesity, the non-peptide chemistry, and the explicit focus on affordability and mass adoption.
The efficacy is only 10 to 16 percent. That seems low.
It is lower than some injectables. But for someone who won't take an injection at all, 10 percent weight loss is infinitely better than zero. The market expansion isn't about converting existing patients—it's about reaching people who were never going to use needles.
What's the real barrier to adoption then?
Tolerability and bioavailability. Oral formulations may cause worse nausea and vomiting. And some patients may find daily pills harder to stick with than a once-weekly injection. The convenience argument cuts both ways.
So this could fail?
It could underperform expectations. But the sheer number of candidates in the pipeline, the alignment with India's oral-medicine preference, and the cost advantage suggest something real is shifting. Whether it's revolutionary or merely incremental depends on execution and real-world tolerability data.
What happens to the injectable market?
It doesn't disappear. Lilly's own statement makes clear that oral formulations will complement, not replace, their injectable portfolio. Both will coexist, serving different patient populations and preferences.